Category: Shroom Boom
-
![Pure Extracts (PULL.C) begins mushroom build-out]()
Pure Extracts (PULL.C) begins mushroom build-out
Pure Extracts is targeting the commercial cannabis and psychedelics sector, backed by deep extraction and production expertise.
-
Revive Therapeutics (RVV.C) shareholders experience intense vertigo
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space.
-
![Core One Labs (COOL.C) unhalted today, and it will be a horror show: But that’s okay]()
Core One Labs (COOL.C) unhalted today, and it will be a horror show: But that’s okay
Halted since July of this year, right in the midst of a six week rise, the pubco formerly known as Lifestyle Delivery Systems, now Core One Labs (COOL.C), unhalted today and, as expected, took an immediate stock price dive. Having shut the door to trading in July at $0.73 as the exchange enforced a change…
-
Numinus Wellness (NUMI.V) to partner on MDMA psychotherapy trial for PTSD patients
If this was a 1990’s news website we’d be putting all sorts of animated siren gifs all over the top of this piece because, I ain’t gonna lie: It’s a big one. Numinus Wellness (NUMI.V), who we’ve been eyeing at a distance for some time because we love shrooms as an industry but don’t trust…
-
Cannabis extractor Pure Extracts (PULL.C) stakes claim in the rocketing mushroom space
Barely a few weeks after telling the Equity.Guru audience that the timeline on mushrooms would see Pure Extracts (PULL.C) focusing on its core cannabis market, evolving market dynamics and a renewed focus on the potential of psychedelics have seen the company hit the gas on its long term shroom plans. With interest in functional and…
-
Delic Holdings (DELC.C) emerges as a psychedelics play aimed at executing real, legal business, and right now
Smallcap investors largely see the psychedelics space in one of two ways; you’re either in the ‘this may be big one day but there’s not a lot of fat on the bones just yet so I’ll wait’ camp, or the ‘fat schmat, everything is a trade and who cares about tomorrow’ camp. I’m pegged pretty…
-
Pure Extracts (PULL.C) goes public with profit-focused cannabis (and mushroom) extraction business model
Yeah, I know, I know. Canadian cannabis companies are ass right now, and have been for a few years. Trust me, I’m about as out of the LP business now as I’ve ever been, but you’d also be an idiot to tar every cannabis company with the same brush, because not every deal involves growing…
-
Revive Therapeutics (RVV.C) to have 10 clinical COVID-19 FDA trial sites by end of year
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the thought that a three time loser might be relevant in 2020. Having missed on an earlier pharma focus, and come to the cannabis party a little…
-
Revive (RVV.C) advances drug delivery tech for psychedelics
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
-
Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the use of its Bucillamine medication as a potential treatment for patients with mild to moderate COVID-19. The U.S. Food and Drug Administration (FDA) has approved Revive…
